GlaxoSmithKline Plc has entered a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients. To date, two cell therapies have been approved for blood-borne cancers, but engineered T cells have not yet delivered strong clinical activity in solid tumours. Improving the fitness of T cells and delaying the onset of T cell exhaustion could help engineered T cell therapies become more effective, GSK said.
